EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies

Samuel Gebhardt, Marine Le Clech, Barbara Höllbacher, Sarah Brunner, Ahmet Varol, Simone Lang, Silvia Jenni, Stefanie Briner, Emilio Yángüez, Tamara Hüsser, Ioana Domocos, Ria Tauscher und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-013989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Samuel Gebhardt und 14 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland samuel.gebhardt@roche.com. Hauptthemen laut MEDLINE: Immunotherapy, Antigens, Neoplasm, T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Humanized mice are highly valuable models for the preclinical development of cancer immunotherapies. However, conventional models often fail to mount robust and trackable tumor antigen-specific (TA-specific) T-cell responses, which hinders the comprehensive evaluation of therapies that depend on this endogenous antitumor immunity.

Methods

To address this limitation, we generated a humanized mouse model by engrafting immunodeficient mice with human hematopoietic stem cells that were transduced with predefined T-cell receptor (TCR) specificities. This approach enables the de novo generation of naïve, functional TA-specific T cells at adjustable frequencies.

Results

We found that transgene-bearing human thymocytes have a developmental advantage in the murine thymus, likely due to the early formation of the transgenic TCR and associated autonomous signaling. In tumor studies, the presence of these TA-specific T cells delayed tumor growth and promoted increased phenotypic diversity of intratumoral T cells, including the formation of PD-1 + /TCF1 + precursor exhausted T cells, which were absent in control mice. We demonstrate the utility of this model in two distinct therapeutic contexts. First, we found that high baseline frequencies of TA-specific T cells blunted the efficacy of a T-cell bispecific antibody (TCB), suggesting that pre-existing exhaustion limits TCB activity. Furthermore, the model enabled the evaluation of costimulatory agonists (FAP-CD40 and FAP-4-1BBL), and demonstrated their dependence on this T-cell compartment for antitumor efficacy.

Conclusions

This adaptable and physiologically relevant model provides a platform to dissect the complex interplay between human tumors, immune cells, and immunotherapies and has the potential to significantly improve the translation of preclinical findings to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyAntigens, NeoplasmT-LymphocytesNeoplasmsAnimalsHumansMiceDisease Models, AnimalReceptors, Antigen, T-CellMice, TransgenicT-Cell Exhaustion

Stichwörter der Autor:innen

Bispecific T cell engager - BiTECombination therapyImmunotherapyT cell Receptor - TCRTumor infiltrating lymphocyte - TIL

Substanzen

Antigens, NeoplasmReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland samuel.gebhardt@roche.com.
  • Institute of Experimental Immunology, University of Zurich, Zürich, Switzerland.
  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.

Förderung

  • Roche

Zitieren

APA

Gebhardt, S., Le Clech, M., Höllbacher, B., Brunner, S., Varol, A., Lang, S., Jenni, S., Briner, S., Yángüez, E., Hüsser, T., Domocos, I., Tauscher, R., Eckmann, J., Münz, C., & Sam, J. (2026). Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013989

Vancouver

Gebhardt S, Le Clech M, Höllbacher B, Brunner S, Varol A, Lang S, et al. Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013989

BibTeX
@article{Gebhardt2026,
  author = {Gebhardt, Samuel and Le Clech, Marine and Höllbacher, Barbara and Brunner, Sarah and Varol, Ahmet and Lang, Simone and Jenni, Silvia and Briner, Stefanie and Yángüez, Emilio and Hüsser, Tamara and Domocos, Ioana and Tauscher, Ria and Eckmann, Jan and Münz, Christian and Sam, Johannes},
  title = {Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-013989}
}
Kostenlos starten →